4832 related articles for article (PubMed ID: 26927811)
1. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study.
Arihiro S; Todo K; Koga M; Furui E; Kinoshita N; Kimura K; Yamagami H; Terasaki T; Yoshimura S; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Nagakane Y; Kameda T; Hasegawa Y; Shibuya S; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Matsuki T; Homma K; Takasugi J; Tokunaga K; Sato S; Kario K; Kitazono T; Toyoda K;
Int J Stroke; 2016 Jul; 11(5):565-74. PubMed ID: 26927811
[TBL] [Abstract][Full Text] [Related]
2. Trends in oral anticoagulant choice for acute stroke patients with nonvalvular atrial fibrillation in Japan: the SAMURAI-NVAF study.
Toyoda K; Arihiro S; Todo K; Yamagami H; Kimura K; Furui E; Terasaki T; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Kameda T; Nagakane Y; Hasegawa Y; Mochizuki H; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Kario K; Sato S; Koga M;
Int J Stroke; 2015 Aug; 10(6):836-42. PubMed ID: 25581108
[TBL] [Abstract][Full Text] [Related]
3. Two-Year Outcomes of Anticoagulation for Acute Ischemic Stroke With Nonvalvular Atrial Fibrillation - SAMURAI-NVAF Study.
Yoshimura S; Koga M; Sato S; Todo K; Yamagami H; Kumamoto M; Itabashi R; Terasaki T; Kimura K; Yagita Y; Shiokawa Y; Kamiyama K; Okuda S; Okada Y; Takizawa S; Hasegawa Y; Kameda T; Shibuya S; Nagakane Y; Ito Y; Matsuoka H; Takamatsu K; Nishiyama K; Fujita K; Kamimura T; Ando D; Ide T; Yoshimoto T; Shiozawa M; Matsubara S; Yamaguchi Y; Kinoshita N; Matsuki T; Takasugi J; Tokunaga K; Higashida K; Homma K; Kario K; Arihiro S; Toyoda K;
Circ J; 2018 Jun; 82(7):1935-1942. PubMed ID: 29863095
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
Coleman CI; Peacock WF; Bunz TJ; Alberts MJ
Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814
[TBL] [Abstract][Full Text] [Related]
5. Nonvitamin-K-antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and previous stroke or transient ischemic attack: An updated systematic review and meta-analysis of randomized controlled trials.
Ntaios G; Papavasileiou V; Diener HC; Makaritsis K; Michel P
Int J Stroke; 2017 Aug; 12(6):589-596. PubMed ID: 28730948
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
[No Abstract] [Full Text] [Related]
7. Major Bleeding Complications and Persistence With Oral Anticoagulation in Non-Valvular Atrial Fibrillation: Contemporary Findings in Real-Life Danish Patients.
Lamberts M; Staerk L; Olesen JB; Fosbøl EL; Hansen ML; Harboe L; Lefevre C; Evans D; Gislason GH
J Am Heart Assoc; 2017 Feb; 6(2):. PubMed ID: 28196815
[TBL] [Abstract][Full Text] [Related]
8. Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials.
Renda G; di Nicola M; De Caterina R
Am J Med; 2015 Sep; 128(9):1007-14.e2. PubMed ID: 25910790
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of Left Atrial Appendage Closure With the WATCHMAN Device Compared With Warfarin or Non-Vitamin K Antagonist Oral Anticoagulants for Secondary Prevention in Nonvalvular Atrial Fibrillation.
Reddy VY; Akehurst RL; Amorosi SL; Gavaghan MB; Hertz DS; Holmes DR
Stroke; 2018 Jun; 49(6):1464-1470. PubMed ID: 29739915
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
Yao X; Abraham NS; Sangaralingham LR; Bellolio MF; McBane RD; Shah ND; Noseworthy PA
J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27412905
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of non-vitamin K oral anticoagulant treatment compared with warfarin in patients with non-valvular atrial fibrillation who develop acute ischemic stroke or transient ischemic attack: a multicenter prospective cohort study (daVinci study).
Saji N; Kimura K; Tateishi Y; Fujimoto S; Kaneko N; Urabe T; Tsujino A; Iguchi Y;
J Thromb Thrombolysis; 2016 Nov; 42(4):453-62. PubMed ID: 27207691
[TBL] [Abstract][Full Text] [Related]
12. Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis.
Ntaios G; Papavasileiou V; Makaritsis K; Vemmos K; Michel P; Lip GYH
Stroke; 2017 Sep; 48(9):2494-2503. PubMed ID: 28716982
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
Larsen TB; Skjøth F; Nielsen PB; Kjældgaard JN; Lip GY
BMJ; 2016 Jun; 353():i3189. PubMed ID: 27312796
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
[TBL] [Abstract][Full Text] [Related]
15. Selection of Oral Anticoagulants in Ischemic Stroke Patients with Nonvalvular Atrial Fibrillation.
Deguchi I; Tanahashi N; Takao M
J Stroke Cerebrovasc Dis; 2018 Oct; 27(10):2627-2631. PubMed ID: 29970321
[TBL] [Abstract][Full Text] [Related]
16. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
[TBL] [Abstract][Full Text] [Related]
17. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Hylek E; Kowey PR; Mahaffey KW; O'Brien EC; Singer DE; Peterson ED; Piccini JP;
Am Heart J; 2017 Jul; 189():40-47. PubMed ID: 28625380
[TBL] [Abstract][Full Text] [Related]
18. Safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in real-world patients with non-valvular atrial fibrillation: a retrospective analysis of contemporary Japanese administrative claims data.
Kohsaka S; Katada J; Saito K; Jenkins A; Li B; Mardekian J; Terayama Y
Open Heart; 2020; 7(1):e001232. PubMed ID: 32341789
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and Safety of Contemporary Oral Anticoagulants Among Asians With Nonvalvular Atrial Fibrillation.
Lee SR; Choi EK; Kwon S; Han KD; Jung JH; Cha MJ; Oh S; Lip GYH
Stroke; 2019 Aug; 50(8):2245-2249. PubMed ID: 31208303
[TBL] [Abstract][Full Text] [Related]
20. Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis.
Pan KL; Singer DE; Ovbiagele B; Wu YL; Ahmed MA; Lee M
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28720644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
